<DOC>
	<DOC>NCT01878318</DOC>
	<brief_summary>This open-label, single arm study will evaluate the effect of RoActemra/Actemra in combination with methotrexate on articular damage in the hand (synovitis/osteitis and erosions) in patients with moderate to severe rheumatoid arthritis who have an inadequate response to non-biological disease-modifying ante-rheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for 24 weeks.</brief_summary>
	<brief_title>A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Diagnosis of rheumatoid arthritis according to ACR/EULAR classification (2010) of &gt;/= 6 months duration Active moderate to severe rheumatoid arthritis (DAS &gt;/= 3.2) Swollen joint count (SJC) &gt;/= 6, tender joint count &gt;/= 8 Synovitis in the dominant hand Inadequate response to stable dose of a nonbiological DMARD for at least 3 months Oral corticosteroids must have been on stable dose for at least 25 out of 28 days before first dose of study drug Patient on outpatient treatment Major surgery (including joint surgery) in the 8 weeks prior to screening, or planned major surgery within 6 months of randomization Rheumatic autoimmune disease other than rheumatoid arthritis American College of Rheumatology (ACR) functional class IV History of or current inflammatory joint disease other than rheumatoid arthritis Previous inadequate response to a biologic DMARD; prior biologic therapy for no longer than 1 month is allowed if discontinued for reasons of tolerability at least 6 months prior to study recruitment Intraarticular or parenteral corticosteroids within 6 weeks prior to study start Inadequate hematologic, renal or liver function Positive for hepatitis B, hepatitis C or HIV infection Pregnant or lactating women History of severe allergic reactions or anaphylaxis to human, humanized or mural monoclonal antibodies Current infections or history of recurrent infections History of or currently active primary or acquired immunodeficiency Active tuberculosis requiring treatment in the previous 3 years Body weight &gt; 150 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>